AstraZeneca and GSK shares fall after positive first-quarter results

14 articles · Updated · The Wall Street Journal · Apr 29

AstraZeneca shares dropped up to 1.5% and GSK shares up to 2.5% despite both companies beating Q1 expectations and reiterating full-year guidance.
Investors appeared disappointed that neither company upgraded their earnings outlook, even as AstraZeneca delayed key lung cancer study results to 2027 and GSK’s new CEO highlighted recent acquisitions.
Analysts note strong product sales and regulatory approvals for AstraZeneca, while GSK’s new leadership and strategic dealmaking signal confidence, yet market reactions remain negative amid unchanged guidance.

Why did GSK's shares plunge nearly 8% despite strong Q1 results and a promising drug pipeline?

Will delayed clinical trial readouts at AstraZeneca impact its dominance in the fast-growing oncology market?

How might rising UK interest rates and energy prices reshape investor sentiment toward traditionally defensive healthcare stocks?

Could aggressive biosimilar price cuts at Sandoz threaten long-term revenue growth, even as volumes rise?

Are investors undervaluing the long-term R&D and AI-driven strategies these pharma giants are pursuing?

As mild flu seasons hurt consumer health sales, could innovation in vaccines or diagnostics offset future volume declines?